23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Focus

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Focus.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Try Life Science Focus now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Lilly’s new weight-loss pill recommended for EU approval

EMA backs Revolution’s pancreatic cancer drug after rapid review

Finnish biotech raises 28 million euros for next-generation allergy treatments
Advertisement

Lundbeck sells off factory in Italy
Sponsored content News from our members
Aurevia

Medical Device Software Process Design: Why IEC 62304 Matters
OEM Automatic AB

Kostnadseffektiv automation för framtidens företag
Aurevia

Your Partner for Clinical Study Submissions and Regulatory Interactions
OEM Automatic AB

Rätt nivåmätning för en säkrare och mer tillförlitlig process
Carl Zeiss AB

ZEISS Innovation Summit 2026 brings together international experts from industry and research
See all announcements

Zealand Pharma enters partnerships worth up to USD 1.2 bn
Advertisement
Opinion

Swedish Life Science industry needs more than another funding wish list
Advertisement

Oncopeptides raises SEK 100 million after brain cancer breakthrough
In Focus

Labour drug shortage in Sweden could be fixed by looking towards Denmark
Advertisement
Medtech

This is how Denmark wants to renegotiate the MDR
Advertisement
Advertisement

Teva wins FDA approval for schizophrenia injection
Advertisement

Xbrane reaches milestone with biosimilar to blockbuster cancer drug

Bristol Myers Squibb reports dual Phase III success
Advertisement

Decision on rival CAR-T therapies: Yes to Yescarta, no to Breyanzi
Advertisement

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.062|